The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands of percent.

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.

FTC said the "Big 3 PBMs" — CVS’s Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx — imposed markups of hundreds to thousands of percent on critical drugs, including those ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" prescription price hikes of 1,000% or more.

FTC Chair Lina Khan has the big three pharmacy benefit managers in sight—UnitedHealth's OptumRx, Cigna's Express Scripts and CVS Caremark Rx. © 2024 Fortune Media ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

According to the FTC report, UnitedHealth’s OptumRx, along with Cigna’s Express Scripts and CVS Caremark Rx, were able to collectively pocket $7.3 billion in added revenue above cost during the five year period of the study through 2022. “The Big 3 ...

Leerink Partners maintained a Market Perform rating on CVS Health (NYSE:CVS) shares while increasing the price target from $51.00 to $55.00. The adjustment reflects the firm's expectation of an earnings recovery despite ongoing challenges within the Health Care Benefits (HCB) sector.

Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical lawsuits against the biggest insulin makers and against the pharmacy middlemen that decide whether to cover the drugmakers’ products.